Pituitary-directed medical therapy in Cushing’s disease

Stephan Petersenn, Maria Fleseriu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Transsphenoidal surgery remains the first line therapy in Cushing’s disease, but a large number of patients will not be cured or disease will recur over time. Repeat pituitary surgery, bilateral adrenalectomy, and radiation have limitations with respect to efficacy and/or side effects. Therefore, there is a clear need for an effective medical treatment. The studies reviewed here suggest a role for pituitary-directed therapies, applying multireceptor ligand somatostatin analogs like pasireotide or second-generation dopamine agonists. Retinoic acid has been also studied in a small prospective study. These compounds target ACTH-secretion at the pituitary level and possibly inhibit corticotrope proliferation. Specific side effects of these compounds need to be considered, especially when used as long-term therapy. These novel approaches could provide options for treatment of patients in whom surgery has failed or is not possible, and while awaiting effects of radiation therapy. Preoperative use to decrease cortisol excess, potentially reducing perioperative complications, needs to be further studied.

Original languageEnglish (US)
Pages (from-to)238-244
Number of pages7
JournalPituitary
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Pituitary ACTH Hypersecretion
Therapeutics
Adrenalectomy
Dopamine Agonists
Tretinoin
Somatostatin
Reoperation
Adrenocorticotropic Hormone
Hydrocortisone
Radiotherapy
Prospective Studies
Ligands

Keywords

  • Cushing’s disease
  • Dopamine agonist
  • Pasireotide
  • Pituitary adenoma
  • Somatostatin analog

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Pituitary-directed medical therapy in Cushing’s disease. / Petersenn, Stephan; Fleseriu, Maria.

In: Pituitary, Vol. 18, No. 2, 01.04.2015, p. 238-244.

Research output: Contribution to journalArticle

Petersenn, Stephan ; Fleseriu, Maria. / Pituitary-directed medical therapy in Cushing’s disease. In: Pituitary. 2015 ; Vol. 18, No. 2. pp. 238-244.
@article{ceba58049a3f4b189768dd934ddf1bc3,
title = "Pituitary-directed medical therapy in Cushing’s disease",
abstract = "Transsphenoidal surgery remains the first line therapy in Cushing’s disease, but a large number of patients will not be cured or disease will recur over time. Repeat pituitary surgery, bilateral adrenalectomy, and radiation have limitations with respect to efficacy and/or side effects. Therefore, there is a clear need for an effective medical treatment. The studies reviewed here suggest a role for pituitary-directed therapies, applying multireceptor ligand somatostatin analogs like pasireotide or second-generation dopamine agonists. Retinoic acid has been also studied in a small prospective study. These compounds target ACTH-secretion at the pituitary level and possibly inhibit corticotrope proliferation. Specific side effects of these compounds need to be considered, especially when used as long-term therapy. These novel approaches could provide options for treatment of patients in whom surgery has failed or is not possible, and while awaiting effects of radiation therapy. Preoperative use to decrease cortisol excess, potentially reducing perioperative complications, needs to be further studied.",
keywords = "Cushing’s disease, Dopamine agonist, Pasireotide, Pituitary adenoma, Somatostatin analog",
author = "Stephan Petersenn and Maria Fleseriu",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s11102-015-0639-4",
language = "English (US)",
volume = "18",
pages = "238--244",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Pituitary-directed medical therapy in Cushing’s disease

AU - Petersenn, Stephan

AU - Fleseriu, Maria

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Transsphenoidal surgery remains the first line therapy in Cushing’s disease, but a large number of patients will not be cured or disease will recur over time. Repeat pituitary surgery, bilateral adrenalectomy, and radiation have limitations with respect to efficacy and/or side effects. Therefore, there is a clear need for an effective medical treatment. The studies reviewed here suggest a role for pituitary-directed therapies, applying multireceptor ligand somatostatin analogs like pasireotide or second-generation dopamine agonists. Retinoic acid has been also studied in a small prospective study. These compounds target ACTH-secretion at the pituitary level and possibly inhibit corticotrope proliferation. Specific side effects of these compounds need to be considered, especially when used as long-term therapy. These novel approaches could provide options for treatment of patients in whom surgery has failed or is not possible, and while awaiting effects of radiation therapy. Preoperative use to decrease cortisol excess, potentially reducing perioperative complications, needs to be further studied.

AB - Transsphenoidal surgery remains the first line therapy in Cushing’s disease, but a large number of patients will not be cured or disease will recur over time. Repeat pituitary surgery, bilateral adrenalectomy, and radiation have limitations with respect to efficacy and/or side effects. Therefore, there is a clear need for an effective medical treatment. The studies reviewed here suggest a role for pituitary-directed therapies, applying multireceptor ligand somatostatin analogs like pasireotide or second-generation dopamine agonists. Retinoic acid has been also studied in a small prospective study. These compounds target ACTH-secretion at the pituitary level and possibly inhibit corticotrope proliferation. Specific side effects of these compounds need to be considered, especially when used as long-term therapy. These novel approaches could provide options for treatment of patients in whom surgery has failed or is not possible, and while awaiting effects of radiation therapy. Preoperative use to decrease cortisol excess, potentially reducing perioperative complications, needs to be further studied.

KW - Cushing’s disease

KW - Dopamine agonist

KW - Pasireotide

KW - Pituitary adenoma

KW - Somatostatin analog

UR - http://www.scopus.com/inward/record.url?scp=84939939290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939939290&partnerID=8YFLogxK

U2 - 10.1007/s11102-015-0639-4

DO - 10.1007/s11102-015-0639-4

M3 - Article

C2 - 25627118

AN - SCOPUS:84939939290

VL - 18

SP - 238

EP - 244

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -